← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Shift Pharmaceuticals Holdings, Inc.
Columbia, MO
$1,157,869
Total funding
4
Grants
Funding over time
peak $360.9K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,157,869 · 4
By mechanism
R43$484,693 · 2
U44$360,937 · 1
R41$312,239 · 1
Investigators at Shift Pharmaceuticals Holdings, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.$360,937
U44 · FY2023 · NS
Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss$312,239
R41 · FY2025 · EY
Development of novel ASO-based therapeutics for CMT1A$256,580
R43 · FY2022 · NS
Multi-dose pre-clinical studies in rat for E1-targeting antisense oligonucleotides$228,113
R43 · FY2019 · NS